Heron Therapeutics, Inc.
HRTX Nasdaq
SEC CIK 818033
Follow Heron Therapeutics
Weekly email: filings, results
Revenue, last quarter
$35.3M
−7.8% vs same quarter last year
Net income
−$5M
+71.4% vs same quarter last year
EPS, diluted
−$0.03
+70% vs same quarter last year
Operating cash flow
−$794K
−159.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $154.9M | −$20M |
| FY24 | $144.3M | −$14M |
| FY23 | $127M | −$111M |
| FY22 | $107.7M | −$182M |
| FY21 | $86.3M | −$221M |
| FY20 | $88.6M | −$227.3M |
| FY19 | $146M | −$204.7M |
| FY18 | $77.5M | −$178.8M |
| FY17 | $30.8M | −$197.5M |
| FY16 | $1.3M | −$173.1M |
| FY15 | - | −$97.6M |
| FY14 | - | −$76.4M |
| FY13 | - | −$55.3M |
| FY12 | - | −$23.3M |
| FY11 | - | −$11.8M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 73.3% | −1.6% | −12.9% |
| FY24 | 73.2% | −8% | −9.7% |
| FY23 | 48.8% | −87.1% | −87.4% |
| FY22 | 49% | −162.2% | −169% |
| FY21 | 46.7% | −252.3% | −255.9% |
| FY20 | 59.2% | −257.4% | −256.4% |
| FY19 | 57.8% | −144.3% | −140.3% |
| FY18 | 64.5% | −237.4% | −230.8% |
| FY17 | 85.1% | −632.4% | −641.9% |
| FY16 | 97.3% | −13363.2% | −13537.4% |
| FY15 | - | - | - |
| FY14 | - | - | - |
| FY13 | - | - | - |
| FY12 | - | - | - |
| FY11 | - | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$27.9M |
| FY24 | −$24.2M |
| FY23 | −$60.3M |
| FY22 | −$148.7M |
| FY21 | −$206.4M |
| FY20 | −$191.6M |
| FY19 | −$131.7M |
| FY18 | −$201M |
| FY17 | −$172.9M |
| FY16 | −$137.2M |
| FY15 | −$79.6M |
| FY14 | −$61.7M |
| FY13 | −$42.4M |
| FY12 | −$18M |
| FY11 | −$8.2M |
- Heron Therapeutics
- Healthcare median
Show the numbers
| Year | Heron Therapeutics | Healthcare median |
|---|---|---|
| FY25 | −12.9% | −30.6% |
| FY24 | −9.7% | −47% |
| FY23 | −87.4% | −58% |
| FY22 | −169% | −80.4% |
| FY21 | −255.9% | −71.9% |
| FY20 | −256.4% | −62.2% |
| FY19 | −140.3% | −46.3% |
| FY18 | −230.8% | −49.6% |
| FY17 | −641.9% | −45.9% |
| FY16 | −13537.4% | −36% |
| FY15 | - | −38.4% |
| FY14 | - | −35.5% |
| FY13 | - | −37.1% |
| FY12 | - | −29.1% |
| FY11 | - | −27.9% |